208 related articles for article (PubMed ID: 12740756)
21. RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia.
Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Huang CH; Tsai GE
J Clin Psychopharmacol; 2008 Feb; 28(1):64-8. PubMed ID: 18204343
[TBL] [Abstract][Full Text] [Related]
22. Amisulpride: a review of its efficacy in schizophrenia.
Möller HJ
Acta Psychiatr Scand Suppl; 2000; 400():17-22. PubMed ID: 10823307
[TBL] [Abstract][Full Text] [Related]
23. A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia.
Perez V; Cañas F; Tafalla M;
Int Clin Psychopharmacol; 2008 May; 23(3):138-49. PubMed ID: 18408528
[TBL] [Abstract][Full Text] [Related]
24. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
25. Clinical evaluation of risperidone in Asian patients with schizophrenia in Singapore.
Chong SA; Yap HL; Low BL; Choo CH; Chan AO; Wong KE; Mahendran R; Chee KT
Singapore Med J; 1999 Jan; 40(1):41-3. PubMed ID: 10361485
[TBL] [Abstract][Full Text] [Related]
26. Gender-specific effects in the treatment of acute schizophrenia with risperidone.
Raedler TJ; Schreiner A; Naber D; Wiedemann K
Pharmacopsychiatry; 2006 Sep; 39(5):171-4. PubMed ID: 16944407
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
Buckley PF
Curr Med Res Opin; 2004 Sep; 20(9):1357-63. PubMed ID: 15383183
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the use of the positive and negative syndrome scale-excited component as a criterion for administration of p.r.n. medication.
Chaichan W
J Psychiatr Pract; 2008 Mar; 14(2):105-13. PubMed ID: 18360196
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
Lasser RA; Bossie CA; Zhu Y; Gharabawi G; Eerdekens M; Davidson M
Int J Geriatr Psychiatry; 2004 Sep; 19(9):898-905. PubMed ID: 15352149
[TBL] [Abstract][Full Text] [Related]
30. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics.
Henderson DC; Goff DC
J Clin Psychiatry; 1996 Sep; 57(9):395-7. PubMed ID: 9746446
[TBL] [Abstract][Full Text] [Related]
31. Treatment of agitation and aggression in bipolar mania: efficacy of quetiapine.
Buckley PF; Paulsson B; Brecher M
J Affect Disord; 2007; 100 Suppl 1():S33-43. PubMed ID: 17376537
[TBL] [Abstract][Full Text] [Related]
32. Effects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophrenia.
Nakanishi S; Kunugi H; Murray RM; Nojima S; Ogawa T; Takahashi T
Psychiatry Clin Neurosci; 2006 Dec; 60(6):751-7. PubMed ID: 17109710
[TBL] [Abstract][Full Text] [Related]
33. [Long-term relapse prevention with risperidone in 215 schizophrenic patients].
Udina Abelló C; Roca Bennasar M; Octavio Del Valle I
Actas Esp Psiquiatr; 2001; 29(4):243-9. PubMed ID: 11470059
[TBL] [Abstract][Full Text] [Related]
34. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
Parellada E; Andrezina R; Milanova V; Glue P; Masiak M; Turner MS; Medori R; Gaebel W
J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
[TBL] [Abstract][Full Text] [Related]
35. Long-term treatment with long-acting risperidone in Korean patients with schizophrenia.
Lee MS; Ko YH; Lee SH; Seo YJ; Kim SH; Joe SH; Han CS; Lee JH; Jung IK
Hum Psychopharmacol; 2006 Aug; 21(6):399-407. PubMed ID: 16915580
[TBL] [Abstract][Full Text] [Related]
36. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
[TBL] [Abstract][Full Text] [Related]
37. Risperidone in the treatment of first episode psychosis.
Yap HL; Mahendran R; Lim D; Liow PH; Lee A; Phang S; Tiong A
Singapore Med J; 2001 Apr; 42(4):170-3. PubMed ID: 11465317
[TBL] [Abstract][Full Text] [Related]
38. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
Kopala LC; Fredrikson D; Good KP; Honer WG
Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777
[No Abstract] [Full Text] [Related]
39. [Long term evolution of the incapacity in schizophrenic patients in maintenance treatment with risperidone].
Bobes J; González MP; Gibert J; Gutiérrez M; Herráiz ML
Actas Esp Psiquiatr; 1999; 27(1):1-7. PubMed ID: 10380141
[TBL] [Abstract][Full Text] [Related]
40. Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia.
Lane HY; Chang YC; Cheng YC; Liu GC; Lin XR; Chang WH
J Clin Psychiatry; 2003 Mar; 64(3):316-20. PubMed ID: 12716274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
